TCM
Tang Capital Management Portfolio holdings
AUM
$1.98B
This Quarter Return
+21.98%
1 Year Return
+21.62%
3 Year Return
+290.69%
5 Year Return
+284.46%
10 Year Return
+928.34%
AUM
$679M
AUM Growth
+$679M
(+1.2%)
Cap. Flow
-$52.2M
Cap. Flow
% of AUM
-7.69%
Top 10 Holdings %
Top 10 Hldgs %
38.68%
Holding
124
New
21
Increased
24
Reduced
16
Closed
25
Top Buys
| 1 |
InflaRx
IFRX
|
$12.9M |
| 2 |
Verastem
VSTM
|
$8.48M |
| 3 |
Atea Pharmaceuticals
AVIR
|
$7.57M |
| 4 |
BioCryst Pharmaceuticals
BCRX
|
$5.98M |
| 5 |
ADMA Biologics
ADMA
|
$4.65M |
Top Sells
| 1 |
MEI Pharma
MEIP
|
$31.6M |
| 2 |
Novo Nordisk
NVO
|
$21.5M |
| 3 |
JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
|
$9.81M |
| 4 |
Alnylam Pharmaceuticals
ALNY
|
$9.01M |
| 5 |
BLUE
bluebird bio
BLUE
|
$8.23M |
Sector Composition
| 1 | Healthcare | 92.72% |
| 2 | Financials | 6.8% |
| 3 | Real Estate | 0.3% |
| 4 | Consumer Discretionary | 0.15% |
| 5 | Utilities | 0.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
AnaptysBio
ANAB
$569M
| $39.7M | 5.84% | 1,950,609 -81,952 | -4% | -$1.67M |
|
2
Tarsus Pharmaceuticals
TARS
$2.47B
| $32.1M | 4.73% | 1,779,158 -255,000 | -13% | -$4.61M |
|
3
Mirum Pharmaceuticals
MIRM
$3.71B
| $29.4M | 4.33% | 1,137,107 -32,893 | -3% | -$851K |
|
|
IMGN
4
DELISTED
Immunogen Inc
IMGN
| $24.5M | 3.61% | 1,300,000 +25,147 | +2% | +$475K |
|
5
Immunocore
IMCR
$1.62B
| $24.3M | 3.58% | 405,600 | – | – |
|
|
BLUE
6
DELISTED
bluebird bio
BLUE
| $24.3M | 3.58% | 7,382,827 -2,500,000 | -25% | -$8.23M |
|
7
KalVista Pharmaceuticals
KALV
$678M
| $23.9M | 3.51% | 2,651,393 | – | – |
|
8
Axsome Therapeutics
AXSM
$6.05B
| $23M | 3.39% | 320,000 | – | – |
|
9
Evolus
EOLS
$494M
| $22.5M | 3.32% | 3,097,399 -100,000 | -3% | -$727K |
|
|
ITCI
10
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $19M | 2.8% | 300,000 | – | – |
|
|
FLG
11
Flagstar Financial, Inc.
FLG
$5.33B
| $18.1M | 2.66% | 1,606,600 | – | – |
|
|
12
BioCryst Pharmaceuticals
BCRX
$1.74B
| $17.2M | 2.54% | 2,450,000 +850,000 | +53% | +$5.98M |
|
13
Viridian Therapeutics
VRDN
$1.5B
| $16.5M | 2.43% | 692,925 | – | – |
|
|
ONC
14
BeOne Medicines Ltd. American Depositary Shares
ONC
$36.4B
| $15.2M | 2.23% | 85,000 | – | – |
|
15
Vaxcyte
PCVX
$4B
| $15M | 2.21% | 300,000 | – | – |
|
16
Eli Lilly
LLY
$657B
| $14.1M | 2.07% | 30,000 | – | – |
|
|
17
InflaRx
IFRX
$108M
| $12.9M | 1.9% | +2,900,000 | New | +$12.9M |
|
18
AstraZeneca
AZN
$248B
| $12.2M | 1.79% | 170,000 | – | – |
|
19
CytomX Therapeutics
CTMX
$336M
| $11.4M | 1.67% | 6,600,000 +506,968 | +8% | +$872K |
|
|
20
Atea Pharmaceuticals
AVIR
$267M
| $11.3M | 1.67% | 3,026,455 +2,023,873 | +202% | +$7.57M |
|
21
BioAtla
BCAB
$26.7M
| $11M | 1.62% | 3,674,076 +50,000 | +1% | +$150K |
|
22
Altimmune
ALT
$338M
| $9.71M | 1.43% | 2,750,000 | – | – |
|
23
Harmony Biosciences
HRMY
$2.12B
| $9.54M | 1.41% | 271,200 -50,000 | -16% | -$1.76M |
|
24
Zymeworks
ZYME
$1.12B
| $9.5M | 1.4% | 1,100,000 | – | – |
|
25
Moderna
MRNA
$9.37B
| $9.32M | 1.37% | 76,700 -60,000 | -44% | -$7.29M |
|